This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oxurion Inkomsten in het verleden

-2.4%

Groei van de winst

-1.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-29.8%
Rendement op eigen vermogen	n/a
Nettomarge	-2,584.9%
Volgende winstupdate	24 Mar 2023

Hoe Oxurion geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:TBGN.F Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Dec 21	1	-29	8	21
30 Sep 21	1	-30	9	22
30 Jun 21	1	-31	9	23
31 Mar 21	2	-29	9	23
31 Dec 20	2	-28	9	22
30 Sep 20	3	-30	10	23
30 Jun 20	3	-32	11	24
31 Mar 20	4	-42	12	25
31 Dec 19	4	-52	13	26
30 Sep 19	4	-54	14	27
30 Jun 19	3	-57	14	28
31 Mar 19	4	-48	13	29
31 Dec 18	5	-38	13	30
30 Sep 18	6	-8	12	28
30 Jun 18	7	23	11	26
31 Mar 18	6	23	11	25
31 Dec 17	6	23	10	23
30 Sep 17	6	-19	10	23
30 Jun 17	6	-61	11	23
31 Mar 17	6	-60	11	24
31 Dec 16	7	-60	11	25
30 Sep 16	8	-47	14	24
30 Jun 16	9	-34	17	23
31 Mar 16	10	-36	21	22
31 Dec 15	11	-38	26	21

Kwaliteitswinsten: TBGN.F is currently unprofitable.

Groeiende winstmarge: TBGN.F is currently unprofitable.

Winsttrend: TBGN.F is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Versnelling van de groei: Unable to compare TBGN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: TBGN.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).

Hoge ROE: TBGN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.